• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Social Capital Suvretta Holdings Corp. I

    8/26/22 8:32:29 AM ET
    $DNAA
    Get the next $DNAA alert in real time by email
    SC 13G 1 d381862dsc13g.htm SC 13G SC 13G

     

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G

    (Rule 13d-102)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No.    )*

     

     

    Akili, Inc.

    (Name of Issuer)

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

    00974B107

    (CUSIP Number)

    August 19, 2022

    (Date of Event which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☐

    Rule 13d-1(b)

     

      ☑

    Rule 13d-1(c)

     

      ☐

    Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 00974B107    Page 2 of 9

     

      1           

    NAMES OF REPORTING PERSONS

     

    Temasek Holdings (Private) Limited

      2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)  ☐        (b)  ☐

     

      3  

    SEC USE ONLY

     

      4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Republic of Singapore

    NUMBER OF

    SHARES

        BENEFICIALLY    

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5    

    SOLE VOTING POWER

     

    0

       6   

    SHARED VOTING POWER

     

    11,509,122(1)

       7   

    SOLE DISPOSITIVE POWER

     

    0

       8   

    SHARED DISPOSITIVE POWER

     

    10,336,425

      9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    11,509,122(1)

    10  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  ☐

     

    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    13.5%(1)(2)

    12  

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    HC

     

    (1)

    Includes 1,172,697 Earnout Shares (as defined herein). See Item 4.

    (2)

    Based on 85,395,207 shares of the Issuer’s (as defined herein) common stock outstanding as of August 19, 2022, as reported in the Issuer’s registration statement on Form S-1, filed with the Securities and Exchange Commission (the “Commission”) on August 24, 2022.


    CUSIP No. 00974B107    Page 3 of 9

     

      1           

    NAMES OF REPORTING PERSONS

     

    Fullerton Management Pte Ltd

      2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)  ☐        (b)  ☐

     

      3  

    SEC USE ONLY

     

      4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Republic of Singapore

    NUMBER OF

    SHARES

        BENEFICIALLY    

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5    

    SOLE VOTING POWER

     

    0

       6   

    SHARED VOTING POWER

     

    11,509,122(1)

       7   

    SOLE DISPOSITIVE POWER

     

    0

       8   

    SHARED DISPOSITIVE POWER

     

    10,336,425

      9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    11,509,122(1)

    10  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  ☐

     

    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    13.5%(1)(2)

    12  

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    HC

     

    (1)

    Includes 1,172,697 Earnout Shares. See Item 4.

    (2)

    Based on 85,395,207 shares of the Issuer’s common stock outstanding as of August 19, 2022, as reported in the Issuer’s registration statement on Form S-1, filed with the Commission on August 24, 2022.


    CUSIP No. 00974B107    Page 4 of 9

     

      1           

    NAMES OF REPORTING PERSONS

     

    Temasek Life Sciences Private Limited

      2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)  ☐        (b)  ☐

     

      3  

    SEC USE ONLY

     

      4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Republic of Singapore

    NUMBER OF

    SHARES

        BENEFICIALLY    

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5    

    SOLE VOTING POWER

     

    0

       6   

    SHARED VOTING POWER

     

    11,509,122(1)

       7   

    SOLE DISPOSITIVE POWER

     

    0

       8   

    SHARED DISPOSITIVE POWER

     

    10,336,425

      9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    11,509,122(1)

    10  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  ☐

     

    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    13.5%(1)(2)

    12  

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    HC

     

    (1)

    Includes 1,172,697 Earnout Shares. See Item 4.

    (2)

    Based on 85,395,207 shares of the Issuer’s common stock outstanding as of August 19, 2022, as reported in the Issuer’s registration statement on Form S-1, filed with the Commission on August 24, 2022.


    CUSIP No. 00974B107    Page 5 of 9

     

      1           

    NAMES OF REPORTING PERSONS

     

    TLS Beta Pte. Ltd.

      2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)  ☐        (b)  ☐

     

      3  

    SEC USE ONLY

     

      4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Republic of Singapore

    NUMBER OF

    SHARES

        BENEFICIALLY    

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5    

    SOLE VOTING POWER

     

    0

       6   

    SHARED VOTING POWER

     

    11,509,122(1)

       7   

    SOLE DISPOSITIVE POWER

     

    0

       8   

    SHARED DISPOSITIVE POWER

     

    10,336,425

      9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    11,509,122(1)

    10  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  ☐

     

    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    13.5%(1)(2)

    12  

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    CO

     

    (1)

    Includes 1,172,697 Earnout Shares. See Item 4.

    (2)

    Based on 85,395,207 shares of the Issuer’s common stock outstanding as of August 19, 2022, as reported in the Issuer’s registration statement on Form S-1, filed with the Commission on August 24, 2022.


    CUSIP No. 00974B107    Page 6 of 9

     

    Item 1(a).

    Name of Issuer:

    Akili, Inc., a Delaware corporation (the “Issuer”)

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

    125 Broad Street, Fifth Floor, Boston, MA 02110

     

    Item 2(a).

    Name of Person Filing:

    This Schedule 13G is being jointly filed by the following reporting persons (each a “Reporting Person” and collectively, the “Reporting Persons”):

     

      (i)

    Temasek Holdings (Private) Limited (“Temasek Holdings”);

     

      (ii)

    Fullerton Management Pte Ltd (“FMPL”);

     

      (iii)

    Temasek Life Sciences Private Limited (“Temasek Life Sciences”); and

     

      (iv)

    TLS Beta Pte. Ltd. (“TLS Beta”).

     

    Item 2(b).

    Address of Principal Business Office or, if none, Residence:

    Each of the Reporting Persons:

    60B Orchard Road

    #06-18 Tower 2

    The Atrium@Orchard

    Singapore 238891

     

    Item 2(c).

    Citizenship:

    Each of the Reporting Persons: Republic of Singapore

     

    Item 2(d).

    Title of Class of Securities:

    Common Stock, par value $0.0001 per share

     

    Item 2(e).

    CUSIP Number:

    00974B107

     

    Item 3.

    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    Not applicable.

     

    Item 4.

    Ownership.

     

      (a)

    Amount beneficially owned:

    TLS Beta directly owns 10,336,425 shares of the Issuer’s common stock. In addition, 1,172,697 Earnout Shares are deposited into an escrow account for the benefit of TLS Beta pursuant to the Merger Agreement. These Earnout Shares are subject to release from escrow to TLS Beta in three equal tranches upon the daily volume weighted average price of a share of the Issuer’s common stock reaching $15.00/share, $20.00/share and $30.00/share, respectively, over any 20 trading days within any 30 consecutive trading day period following August 19, 2022 and prior to August 19, 2027, in each case, on the terms set forth in the Merger Agreement. Before these Earnout Shares are released, TLS Beta has the power to vote, but not dispose of, these Earnout Shares.

    TLS Beta is a wholly-owned subsidiary of Temasek Life Sciences, which in turn is a wholly-owned subsidiary of FMPL, which in turn is a wholly-owned subsidiary of Temasek Holdings. Temasek Life Sciences, FMPL and Temasek Holdings, through the ownership described herein, may be deemed to beneficially own the shares of the Issuer’s common stock directly owned by TLS Beta.


    CUSIP No. 00974B107    Page 7 of 9

     

      (b)

    Percent of class:

    As of August 25, 2022: 13.5%

    The percentage above is based on 85,395,207 shares of the Issuer’s common stock outstanding as of August 19, 2022, as reported in the Issuer’s registration statement on Form S-1, filed with the Commission on August 24, 2022.

     

      (c)

    Number of shares as to which the person has:

    With respect to the shared power to vote, or to direct the vote, and to dispose, or to direct the disposition of, the shares of the Issuer’s voting common stock, please see Item 4(a) above regarding qualifications as to beneficial ownership.

     

      (i)

    Sole power to vote or to direct the vote:

    0

     

      (ii)

    Shared power to vote or to direct the vote:

    11,509,122

     

      (iii)

    Sole power to dispose or to direct the disposition of:

    0

     

      (iv)

    Shared power to dispose or to direct the disposition of:

    10,336,425

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not Applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

    Not Applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not Applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    Not Applicable.

     

    Item 10.

    Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.


    CUSIP No. 00974B107    Page 8 of 9

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: August 26, 2022     TEMASEK HOLDINGS (PRIVATE) LIMITED
        By:  

    /s/ Jason Norman Lee

        Name:   Jason Norman Lee
        Title:   Authorized Signatory
    Dated: August 26, 2022     FULLERTON MANAGEMENT PTE LTD
        By:  

    /s/ Gregory Tan

        Name:   Gregory Tan
        Title:   Director
    Dated: August 26, 2022     TEMASEK LIFE SCIENCES PRIVATE LIMITED
        By:  

    /s/ Lim Siew Lee Sherlyn

        Name:   Lim Siew Lee Sherlyn
        Title:   Director
    Dated: August 26, 2022     TLS BETA PTE. LTD.
        By:  

    /s/ Zahedah Abdul Rashid

        Name:   Zahedah Abdul Rashid
        Title:   Director


    CUSIP No. 00974B107    Page 9 of 9

     

    LIST OF EXHIBITS

     

    Exhibit No.

      

    Description

    99.1    Joint Filing Agreement, dated as of August 26, 2022, by and among Temasek Holdings, FMPL, Temasek Life Sciences and TLS Beta.
    Get the next $DNAA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DNAA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $DNAA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Social Capital Suvretta Holdings Corp. I

      SC 13G - Akili, Inc. (0001850266) (Subject)

      1/20/23 6:27:44 AM ET
      $DNAA
    • SEC Form SC 13D filed by Social Capital Suvretta Holdings Corp. I

      SC 13D - Akili, Inc. (0001850266) (Subject)

      8/30/22 4:48:09 PM ET
      $DNAA
    • SEC Form SC 13G filed by Social Capital Suvretta Holdings Corp. I

      SC 13G - Akili, Inc. (0001850266) (Subject)

      8/29/22 12:28:20 PM ET
      $DNAA

    $DNAA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • PureTech Health plc – Half-Year Report

      Strong capital base with PureTech Level Cash and Cash Equivalents of $341.4 million1 and Consolidated Cash and Cash Equivalents of $365.9 million2 as of June 30, 2022, excluding up to $115.4 million added post-period3; Operational runway extended into Q1 2026 Significant advancement of PureTech's Wholly Owned Programs, with three clinical trials underway, four completed, and human proof-of-principle achieved for a key PureTech platform Excellent progress across the Founded Entities, including Karuna's positive topline Phase 3 results for KarXT in schizophrenia, Akili's Nasdaq listing and Gelesis' commercial progress with Plenity®4 in the post-period, and four clinical data publications ac

      8/25/22 2:07:00 AM ET
      $CPSR
      $DNAA
      $GLS
      $KRTX
      Business Services
      Finance
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Digital Medicine Leader Akili to List on Nasdaq Following Successful Business Combination with Social Capital Suvretta Holdings Corp. I

      Akili, Inc. common stock to begin trading on Nasdaq under the ticker symbol "AKLI" on August 22, 2022 Total gross proceeds of more than $163 million will support launch of first FDA-cleared video game treatment and advancement of late-stage pipeline Akili, a leading digital medicine company, today completed its previously announced business combination with Social Capital Suvretta Holdings Corp. I ("SCS") (NASDAQ:DNAA), a publicly traded special purpose acquisition company. The newly formed company, Akili, Inc. ("Akili"), is expected to start trading on The Nasdaq Capital Market ("Nasdaq") under the new ticker symbol "AKLI" on August 22, 2022. Akili raised more than $163 million from the

      8/19/22 5:25:00 PM ET
      $DNAA
    • PureTech Founded Entity Akili Announces Public Company Board of Director Nominees

      New and recent director nominees include industry trailblazers BJ Jones of Biohaven Pharmaceuticals; Christine Lemke of Evidation Health; Ken Ehlert, formerly of UnitedHealth Group; and Chamath Palihapitiya of Social Capital and SCS PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company noted that its Founded Entity, Akili Interactive Labs, Inc. ("Akili"), a leading digital medicine company pioneering the development of cognitive treatments through game-changing technologies, today announced the nominees for its future board of directors, effective upon the closing of Akili's business combination with Social Capital Suvretta H

      7/11/22 7:05:00 AM ET
      $DNAA
      $PRTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DNAA
    Financials

    Live finance-specific insights

    See more
    • PureTech Founded Entity Akili Interactive, a Leader in Digital Medicine, to Become Publicly Traded Through Combination with Social Capital Suvretta Holdings Corp. I

      In addition to PureTech's advanced Wholly Owned Pipeline, Founded Entities are an additional source of value and Akili is now set to join the growing list of publicly-traded Founded Entities for PureTech, which also include Karuna Therapeutics (NASDAQ:KRTX), Vor Biopharma (NASDAQ:VOR) and Gelesis (NYSE:GLS) Fully committed PIPE of $162 million led by $100 million from Social Capital with remaining $62 million from new and existing investors including: Suvretta Capital Management's Averill strategy, Apeiron Investment Group, Temasek, co-founder PureTech Health, Polaris Partners, Evidity Health Capital, JAZZ Venture Partners and Omidyar Technology Ventures Transaction values the combined co

      1/26/22 7:02:00 AM ET
      $DNAA
      $GLS
      $KRTX
      $PRTC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Akili Interactive, a Leader in Digital Medicine, to Become Publicly Traded Through Combination with Social Capital Suvretta Holdings Corp. I

      Akili's leading digital therapeutic platform combines science and technology to address cognitive impairments in patients, reimagining how central nervous system medicines are designed, developed, and delivered Transaction will support commercial launch of EndeavorRx®, a first-of-its-kind, FDA-cleared and CE-marked prescription digital therapeutic for pediatric ADHD, as well as advance clinical development pipeline across multiple neuropsychiatric diseases, including expanded ADHD populations, multiple sclerosis, autism, and depression Transaction values the combined company at an equity value post-money of up to approximately $1 billion and is expected to provide up to $412 million in

      1/26/22 7:00:00 AM ET
      $DNAA

    $DNAA
    SEC Filings

    See more
    • SEC Form 424B3 filed by Social Capital Suvretta Holdings Corp. I

      424B3 - Akili, Inc. (0001850266) (Filer)

      1/12/23 8:13:45 AM ET
      $DNAA
    • Social Capital Suvretta Holdings Corp. I filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Akili, Inc. (0001850266) (Filer)

      1/12/23 8:06:32 AM ET
      $DNAA
    • SEC Form 424B3 filed by Social Capital Suvretta Holdings Corp. I

      424B3 - Akili, Inc. (0001850266) (Filer)

      1/5/23 7:21:42 AM ET
      $DNAA

    $DNAA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Jina Anil (Amendment)

      3/A - Akili, Inc. (0001850266) (Issuer)

      12/13/22 8:14:59 PM ET
      $DNAA
    • SEC Form 3 filed by new insider Ehlert Kenneth (Amendment)

      3/A - Akili, Inc. (0001850266) (Issuer)

      12/13/22 8:15:13 PM ET
      $DNAA
    • SEC Form 3 filed by new insider Martucci Walter Edward Ii (Amendment)

      3/A - Akili, Inc. (0001850266) (Issuer)

      12/13/22 8:10:52 PM ET
      $DNAA

    $DNAA
    Leadership Updates

    Live Leadership Updates

    See more
    • PureTech Founded Entity Akili Appoints Game Industry Veteran Behind Bejeweled, Plants vs. Zombies as Chief Product Officer

      Jon David brings deep expertise in building and launching engaging products to the Akili leadership team PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company noted that its Founded Entity, Akili Interactive Labs, Inc. ("Akili"), a leading digital medicine company developing cognitive treatments through game-changing technologies, today announced the appointment of Jon David as Chief Product Officer. In his role, David will be responsible for developing and executing the strategic vision of Akili's future product pipeline as the company continues to lead the way in establishing an entirely new category of medicine - one where

      3/17/22 9:05:00 AM ET
      $DNAA
      $PRTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Game Industry Veteran Behind Bejeweled, Plants vs. Zombies Joins Akili as Chief Product Officer

      Jon David brings deep expertise in building and launching engaging products to the Akili leadership team Akili Interactive ("Akili" or the "Company"), a leading digital medicine company developing cognitive treatments through game-changing technologies, today announced the appointment of Jon David as Chief Product Officer. In his role, David will be responsible for developing and executing the strategic vision of Akili's future product pipeline as the company continues to lead the way in establishing an entirely new category of medicine - one where the treatment is experienced like high-end entertainment. Reporting to the CEO, David will join the Akili executive team, which includes leader

      3/17/22 9:00:00 AM ET
      $DNAA